Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 5
Submit an article Journal homepage
192
Views
12
CrossRef citations to date
0
Altmetric
Theme: Interventional Cardiology - Review

Stent thrombosis: an overview

Marinella Patrizia Centemero Instituto Dante Pazzanese of Cardiologia, 500 Dante Pazzanese Avenue, Sao Paulo, Brazil. [email protected]
&
Jackson Rafael Stadler Instituto Dante Pazzanese of Cardiologia, 500 Dante Pazzanese Avenue, Sao Paulo, Brazil
Pages 599-615 | Published online: 10 Jan 2014

References

  • Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol. 45(12), 2088–2092 (2005).
  • Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52(14), 1134–1140 (2008).
  • Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 115(11), 1433–1439; discussion 1439 (2007).
  • Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98(3), 352–356 (2006).
  • Pfisterer M, Brunner-La Rocca HP, Buser PT et al.; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584–2591 (2006).
  • Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115(11), 1440–1455; discussion 1455 (2007).
  • Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc. Interv. 69(7), 1064–1074 (2007).
  • Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998–1008 (2007).
  • Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 989–997 (2007).
  • Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356(10), 1020–1029 (2007).
  • Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 1030–1039 (2007).
  • Cutlip DE, Windecker S, Mehran R et al.; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17), 2344–2351 (2007).
  • Lepor NE. Primary prevention, treatment, and secondary prevention of late and very late stent thrombosis. Rev. Cardiovasc. Med. 8(Suppl. 1), S27–S33 (2007).
  • Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667–678 (2007).
  • Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome. Coron. Artery Dis. 15(6), 313–318 (2004).
  • Virmani R, Kolodgie FD, Farb A. Drug-eluting stents: are they really safe? Am. Heart Hosp. J. 2(2), 85–88 (2004).
  • Vorpahl M, Yazdani SK, Nakano M et al. Pathobiology of stent thrombosis after drug-eluting stent implantation. Curr. Pharm. Des. 16(36), 4064–4071 (2010).
  • Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J. Am. Coll. Cardiol. 57(4), 390–398 (2011).
  • Siqueira DA, Abizaid AA, Costa Jde R et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur. Heart J. 28(11), 1304–1309 (2007).
  • Hoffmann R, Morice MC, Moses JW et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart 94(3), 322–328 (2008).
  • Hur SH, Ako J, Honda Y, Sudhir K, Fitzgerald PJ. Late-acquired incomplete stent apposition: morphologic characterization. Cardiovasc. Revasc. Med. 10(4), 236–246 (2009).
  • Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46(2), 231–236 (2005).
  • Togni M, Räber L, Cocchia R et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int. J. Cardiol. 120(2), 212–220 (2007).
  • Virchow RLK. Thrombose and embolie: gefässentzündung und septische infection. In: Gesammelte Abhandlungenzur Wissenschaftlichen Medicin. Von Meidinger & Sohn, Frankfurt, Germany, 219–732 (1856).
  • Lemesle G, Delhaye C, Bonello L, de Labriolle A, Waksman R, Pichard A. Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Arch. Cardiovasc. Dis. 101(11–12), 769–777 (2008).
  • Moussa I, Di Mario C, Di Francesco L, Reimers B, Blengino S, Colombo A. Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am. J. Cardiol. 78(3A), 13–17 (1996).
  • Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
  • van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J. Am. Coll. Cardiol. 53(16), 1399–1409 (2009).
  • Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113(8), 1108–1113 (2006).
  • Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation 108(1), 2–5 (2003).
  • de la Torre Hernández JM, Alfonso F, Gimeno F et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc. Interv. 3(9), 911–919 (2010).
  • de la Torre Hernández JM, Alfonso F, Gimeno F et al.; ESTROFA-2 Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio Español sobre Trombosis de stents Farmacoactivos). J. Am. Coll. Cardiol. 51(10), 986–990 (2008).
  • Dangas GD, Caixeta A, Mehran R et al.; Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 123(16), 1745–1756 (2011).
  • King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al.; ACC/AHA/SCAI. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J. Am. Coll. Cardiol. 51(2), 172–209 (2008).
  • Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 31(20), 2501–2555 (2010).
  • Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the ‘optimal’ duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC Cardiovasc. Interv. 2(12), 1279–1285 (2009).
  • Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).
  • Urban P, Abizaid A, Banning A et al.; e-SELECT Investigators. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J. Am. Coll. Cardiol. 57(13), 1445–1454 (2011).
  • Mauri L, Kereiakes DJ, Normand SL et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am. Heart J. 160(6), 1035–1041.e1 (2010).
  • Kimura T, Morimoto T, Kozuma K et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of for review and reevaluation (RESTART) sirolimus-eluting stents: observations from the registry of stent thrombosis. Circulation 122(1), 52–61 (2010).
  • Windecker S, Meier B. Late coronary sent thrombosis. Circulation 116, 1952–1965 (2007).
  • Parodi G, Memisha G, Bellandi B et al. Effectiveness of primary percutaneous coronary interventions for stent thrombosis. Am. J. Cardiol. 103(7), 913–916 (2009).
  • van Werkum JW, Heestermans AA, de Korte FI et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 119(6), 828–834 (2009).
  • Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297(2), 159–168 (2007).
  • McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444), 1519–1521 (2004).
  • Mohammad RA, Goldberg T, Dorsch MP, Cheng JW. Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. Clin. Ther. 32(14), 2265–2281 (2010).
  • Petersen JL, Barron JJ, Hammill BG et al. Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. Am. Heart J. 159(3), 462.e1–470.e1 (2010).
  • Park SJ, Park DW, Kim YH et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med. 362(15), 1374–1382 (2010).
  • Kastrati A, Byrne RA, Schulz S. Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation? JACC Cardiovasc. Interv. 4(10), 1129–1132 (2011).
  • White HD. Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer? Curr. Opin. Cardiol. 26(4), 275–278 (2011).
  • Byrne RA, Schulz S, Mehilli J et al.; for the Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am. Heart J. 157(4), 620–624.e2 (2009).
  • Bates ER, Lau WC, Angiolillo DJ. Clopidogrel–drug interactions. J. Am. Coll. Cardiol. 57(11), 1251–1263 (2011).
  • Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J. Am. Coll. Cardiol. 46(10), 1827–1832 (2005).
  • Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312–2317 (2007).
  • Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53(10), 849–856 (2009).
  • Price MJ, Berger PB, Teirstein PS et al.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097–1105 (2011).
  • Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306(11), 1215–1223 (2011).
  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost. 8(8), 1678–1684 (2010).
  • Alexopoulos D, Dimitropoulos G, Davlouros P et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc. Interv. 4(4), 403–410 (2011).
  • Angiolillo DJ, Saucedo JF, Deraad R et al.; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J. Am. Coll. Cardiol. 56(13), 1017–1023 (2010).
  • James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157(4), 599–605 (2009).
  • Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121(10), 1188–1199 (2010).
  • Meredith IT, Ormiston J, Whitbourn R et al.; ENDEAVOR I Investigators. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am. J. Cardiol. 100(8B), 56M–61M (2007).
  • Fajadet J, Wijns W, Laarman GJ et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EuroIntervention 6(5), 562–567 (2010).
  • Eisenstein EL, Leon MB, Kandzari DE et al.; ENDEAVOR III Investigators. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc. Interv. 2(12), 1199–1207 (2009).
  • Leon MB, Nikolsky E, Cutlip DE et al.; ENDEAVOR IV Investigators. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc. Interv. 3(10), 1043–1050 (2010).
  • Miyazawa A, Ako J, Hongo Y et al.; ENDEAVOR III Investigators. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am. Heart J. 155(1), 108–113 (2008).
  • Waseda K, Miyazawa A, Ako J et al.; ENDEAVOR IV Trial Investigators. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc. Interv. 2(8), 779–784 (2009).
  • Kim JS, Jang IK, Fan C et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc. Interv. 2(12), 1240–1247 (2009).
  • Waksman R. Drug-eluting stents: is new necessarily better? Lancet 372(9644), 1126–1128 (2008).
  • Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644), 1163–1173 (2008).
  • Klauss V, Serruys PW, Pilgrim T et al. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. JACC Cardiovasc. Interv. 4(8), 887–895 (2011).
  • Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur. Heart J. 31(2), 165–176 (2010).
  • Caixeta A, Lansky AJ, Serruys PW et al.; SPIRIT II and III Investigators. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc. Interv. 3(12), 1220–1228 (2010).
  • Smits PC, Kedhi E, Royaards KJ et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). J. Am. Coll. Cardiol. 58(1), 11–18 (2011).
  • Stone GW, Rizvi A, Sudhir K et al.; SPIRIT IV Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J. Am. Coll. Cardiol. 58(1), 19–25 (2011).
  • Stone GW, Kedhi E, Kereiakes DJ et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124(8), 893–900 (2011).
  • Bezenek S, Hermiller J, Lansky A et al. Low stent thrombosis risk with the XIENCE V® everolimus-eluting coronary stent: evidence from randomized and single-arm clinical trials. J. Interv. Cardiol. 24(4), 326–341 (2011).
  • Silber S, Windecker S, Vranckx P, Serruys PW; on behalf of the RESOLUTE All Comers Investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 377(9773), 1241–1247 (2011).
  • Costa JR Jr, Abizaid A, Costa R et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc. Interv. 2(5), 422–427 (2009).
  • Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 123(7), 779–797 (2011).
  • Onuma Y, Serruys PW, Perkins LE et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122(22), 2288–2300 (2010).
  • Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371(9616), 899–907 (2008).
  • Serruys PW, Onuma Y, Ormiston JA et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122(22), 2301–2312 (2010).
  • Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897–910 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.